Download PDF
Dtsch Med Wochenschr 2002; 127(9): 451-456
DOI: 10.1055/s-2002-20427
Übersichten
© Georg Thieme Verlag Stuttgart · New York

Der selektive Tyrosinkinase-Inhibitor Imatinib (STI571) bei hämatologischen und onkologischen Erkrankungen

Selective tyrosinekinase inhibitor imatinib (STI571) in haematological and oncological diseaseA. Hochhaus
  • III. Medizinische Universitätsklinik (Direktor: Prof. Dr. R. Hehlmann), Fakultät für Klinische Medizin Mannheim der Universität Heidelberg
Further Information

Publication History

Manuskript-Eingang: 27. Dezember 2001

Annahme nach Revision: 06. Februar 2002

Publication Date:
28 February 2002 (online)

Also available at
    Permissions and Reprints

Proteinkinasen sind eine große Familie homologer Proteine, die aus zwei Subfamilien, den Serin-Threonin-Kinasen und den Tyrosinkinasen, besteht. Sie sind Teil der Signaltransduktionswege und spielen eine zentrale Rolle in verschiedenen biologischen Prozessen, wie Zellwachstum, Stoffwechsel, Differenzierung und Apoptose. Tyrosinkinasen binden ATP und übertragen Phosphatgruppen von ATP auf Tyrosinreste verschiedener Substrate. Imatinib (Glivec®, früher STI571 oder CGP57148B) ist ein selektiver Inhibitor der strukturell ähnlichen Tyrosinkinasen ABL, PDGF-R und c-kit ([Abb. 1] und [2] ).

Literatur

  • 1 Apperley J F, Schultheis B, Chase A. et al . Chronic myeloproliferative diseases with t(5;12) and a PDGFRb fusion gene: Complete cytogenetic remissions on STI571.  Blood. 2001;  98 (Suppl 1) 726a
    Google Scholar
  • 2 Barthe C, Cony-Makhoul P, Melo J V, Reiffers J, Mahon F X. Roots of clinical resistance to STI-571 cancer therapy.  Science. 2001;  293 2163a
    Google Scholar
  • 3 Beham Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas O A, Linkesch W. Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.  Blood. 2002;  99 381-383
    Google Scholar
  • 4 Brouard M, Saurat J H. Cutaneous reactions to STI571.  N Engl J Med. 2001;  345 618-619
    Google Scholar
  • 5 Buchdunger E, Cioffi C L, Law N, Stover D, Ohno-Jones S, Druker B J, Lydon N B. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.  J Pharmacol Exp Ther. 2000;  295 139-145
    Google Scholar
  • 6 Deininger M WN, Goldman J M, Lydon N, Melo J V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.  Blood. 1997;  90 3691-3698
    Google Scholar
  • 7 Druker B J, Kantarjian H M, Talpaz M, Paquette R, Mauro M J, Rosamilia M, Zoellner U, Resta D, Capdeville R, Sawyers C L. A phase I study of Gleevec (imatinib mesylate) administered concomitantly with cytosine arabinoside (Ara-C) in patients with Philadelphia positive chronic myeloid leukemia (CML).  Blood. 2001;  98 (Suppl 1) 845a-846a
    Google Scholar
  • 8 Druker B J, Lydon N B. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia.  J Clin Invest. 2000;  105 3-7
    Google Scholar
  • 9 Druker B J, Sawyers C L, Kantarjian H, Resta D J, Fernandez Reese S, Ford J M, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.  N Engl J Med. 2001;  344 1038-1042
    Google Scholar
  • 10 Druker B J, Talpaz M, Resta D J, Peng B, Buchdunger E, Ford J M, Lydon N B, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers C L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.  N Engl J Med. 2001;  344 1031-1037
    Google Scholar
  • 11 Druker B J, Tamura S, Buchdunger E, Ohno S, Segal G M, Fanning S, Zimmermann J, Lydon N B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.  Nat Medic. 1996;  2 561-566
    Google Scholar
  • 12 Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, Piotelli P, Pogliani E, Corneo G, Formelli F, D’Incalci M. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571.  J Natl Cancer Inst. 2000;  92 1641-1650
    Google Scholar
  • 13 Gambacorti-Passerini C, le C outre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo G M, Belotti D, Pogliani E, Lydon N B. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.  Blood Cells Mol Diseases. 1997;  23 380-394
    Google Scholar
  • 14 Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, Sawyers C L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.  Science. 2001;  293 876-880
    Google Scholar
  • 15 Hehlmann R, Hochhaus A. Evidenzbasierte Therapie der chronischen myeloischen Leukämie.  Dtsch Ärztebl. 2001;  98 A1834-A1837
    Google Scholar
  • 16 Heinrich M C, Griffith D J, Druker B J, Wait C L, Ott K A, Zigler A J. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor.  Blood. 2000;  96 925-932
    Google Scholar
  • 17 Hochhaus A, Kreil S, Corbin A, La Rosée P, Lahaye T, Berger U, Cross N CP, Linkesch W, Druker B J, Hehlmann R. Roots of clinical resistance to STI-571 cancer therapy.  Science. 2001;  293 2163a
    Google Scholar
  • 18 Joensuu H, Roberts P J, Sarlomo-Rikala M, Andersson L C, Tervahartiala P, Tuveson D, Silberman S L, Capdeville R, Dimitrijevic S, Druker B, Demetri G D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.  N Engl J Med. 2001;  344 1052-1056
    Google Scholar
  • 19 Kano Y, Akutsu M, Tsunoda S, Mano H, Sato Y, Honma Y, Furukawa Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.  Blood. 2001;  97 1999-2007
    Google Scholar
  • 20 Kantarjian H M, Sawyers C L, Hochhaus A, Guilhot F, Schiffer C A, Deininger M W, Gambacorti-Passerini C, Stone R M, Goldman J, Fischer T, Rosamilia M, Zoellner U, Resta D, Capdeville R, Druker B J. GleevecTM (Imatinib mesylate) induced hematologic and cytogenetic responses confirmed and expanded in patients with chronic myeloid leukemia (CML) - A phase II study update.  Blood. 2001;  98 (Suppl 1) 845a
    Google Scholar
  • 21 Kilic T, Alberta J A, Zdunek P R, Acar M, Iannarelli P, O’Reilly T, Buchdunger E, Black P M, Stiles C. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.  Cancer Research. 2000;  60 5143-5150
    Google Scholar
  • 22 Kreil S, Müller M C, Lahaye T, La Rosée P, Corbin A M, Schoch C, Cross N CP, Berger U, Rieder H, Druker B J, Gschaidmeier H, Hehlmann R, Hochhaus A. Molecular and chromosomal mechanisms of resistance in CML patients after STI571 (Glivec) therapy.  Blood. 2001;  98 (Suppl1) 435a
    Google Scholar
  • 23 Krystal G W, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.  Clin Cancer Res. 2000;  6 3319-3326
    Google Scholar
  • 24 Mahon F X, Deininger M WN, Schultheis B, Chabrol J, Reiffers J, Golfdman J M, Melo J V. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.  Blood. 2000;  96 1070-1079
    Google Scholar
  • 25 Merx K, Kreil S, Lahaye T, Müller M C, Paschka P, Schoch C, Weisser A, Kuhn C, Landmann T, Gschaidmeier H, Berger U, Hehlmann R, Hochhaus A. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response to STI571 in chronic phase CML patients.  Blood. 2001;  98 (Suppl 1) 846a-847a
    Google Scholar
  • 26 O’Brien S, Vallance S E, Craddock C, Holyoake T L, Goldman J M. the UK PISCES Group . PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloid leukaemia.  Blood. 2001;  98 (Suppl 1) 846a
    Google Scholar
  • 27 O’Dwyer M E, Mauro M J, Kuyl J M, Paquette R, Sawyers C L, Druker B J. Preliminary evaluation of the combination of imatinib mesylate (Glevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML.  Blood. 2001;  98 (Suppl 1) 846a
    Google Scholar
  • 28 Okuda K, Weisberg E, Gilliland D G, Griffin J D. ARG tyrosine kinase activity is inhibited by STI571.  Blood. 2001;  97 2440-2448
    Google Scholar
  • 29 Ottmann O G, Sawyers C, Druker B, Goldman J, O’Brien S G, Reiffers J, Silver R T, Tura S, Fischer T, Niederwieser D, Schiffer C, Baccarani M, Gratwohl A, Hochhaus A, Reese S F, Capdeville R. Phase II study of STI571 in adult patients with Philadelphia chromosome (Ph) positive acute leukaemias.  Hematol J. 2001;  2 (Suppl 1) 93
    Google Scholar
  • 30 Rubin B P, Singer S, Tsao C, Duensing A, Lux M L, Ruiz R, Hibbard M K, Chen C J, Xiao S, Tuveson D A, Demetri G D, Fletcher D M, Fletcher J A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.  Cancer Res. 2001;  61 8118-8121
    Google Scholar
  • 31 Sawyers C L. Cancer treatment in the STI571 era: What will change?.  J Clin Oncol. 2001;  19 (Suppl 1) 13s-16s
    Google Scholar
  • 32 Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C, Ottmann O G, Schiffer C A, Talpaz M, Guilhot F, Niederwieser D, Ben-Am M, Gathmann I, Ford J, Druker B J. on behalf of the International Gleevec Study Group . Gleevec/Glivec (Imatinib mesylate, STI-571) in patients with chronic myeloid leukemia (CML) in myeloid blast crisis: Updated results of a phase II study.  Blood. 2001;  98 (Suppl 1) 845a
    Google Scholar
  • 33 Silver R T, Woolf S H, Hehlmann R, Appelbaum F R, Anderson J, Bennett C, Goldman J M, Guilhot F, Kantarjian H M, Lichtin A E, Talpaz M, Tura S. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology.  Blood. 1999;  94 1517-1536
    Google Scholar
  • 34 Talpaz M, Silver R T, Druker B, Paquette R, Goldman J M, G ambacorti-Passerini C, Guilhot F, Schiffer C A, Reese S F, Kantarjian H M, Ford J M. GleevecTM (formerly STI571): An active drug in patients with PH+ chronic myeloid leukemia in accelerated phase - updated results of a phase II study.  Blood. 2001;  98 (Suppl 1) 845a
    Google Scholar
  • 35 Thiesing J T, Ohno-Jones S, Kolibaba K S, Druker B J. Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells.  Blood. 2000;  96 3195-3199
    Google Scholar
  • 36 Topaly J, Zeller W, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positivbe chronic myelogenous leukemia cells.  Leukemia. 2001;  15 342-347
    Google Scholar
  • 37 van Oosterom A T, Judson I, Verweij J, Stroobants S, di Paola E D, Dimitrijevic S, Martens M, Webb A, Sciot R, van Glabbeke M, Silberman S, Nielsen O S, for t he European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.  Lancet. 2001;  358 1421-1423
    Google Scholar
  • 38 Weisberg E, Griffin J D. Mechanism of resistence to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.  Blood. 2000;  95 3498-3505
    Google Scholar

Korrespondenz

Priv.-Doz. Dr. med. Andreas Hochhaus

III. Medizinische Universitätsklinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg

Wiesbadener Straße 7-11

68305 Mannheim

Phone: 0621/3832854

Fax: 0621/3833833

Email: hochhaus@uni-hd.de